New antibody therapy targets stubborn autoimmune blood diseases
NCT ID NCT07175493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to check for safety and whether it improves blood cell counts. It is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM336 (a bispecific antibody targeting BCMA and CD3)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat autoimmune blood disorders like ITP or autoimmune hemolytic anemia.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE CYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Blood Disease Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
-
Heping Hospital Affiliated to Changzhi Medical College
RECRUITINGChangzhi, Shanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an RNA 'Message' reprogram the immune system to stop autoimmune blood disorders?
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Can a bispecific antibody tame two autoimmune blood disorders?
- Can a gut bacteria transplant help when steroids fail for a bleeding disorder?
- Can a new drug calm the immune System's attack on blood cells?
- Engineered immune cells take aim at stubborn blood disorder